Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC: Preoperative chemoradiotherapy versus immediate surgery for resectable or borderline resectable pancreatic cancer
NL-OMON45151Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall survival. Started Apr 2013; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON45151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45151.